ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review

By sjmartinez • June 18, 2024

Kathuria-Prakash N, Lopez LP, Raman S, Ye H, Anaokar J, Sisk A, Pantuck AJ, Drakaki A. ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review. JCO Precis Oncol. 2024 Jun;8:e2400154. doi: 10.1200/PO.24.00154. PMID: 38885453.

Tags: Fellow, Hematology/Oncology, Publications

Detecting clinically relevant topological structures in multiplexed spatial proteomics using TopKAT

Samorodnitsky S, Campbell K, Little A, Ling W, Zhao N, Chen YC, Wu MC. Detecting clinically relevant topological structures in multiplexed spatial proteomics using TopKAT.[...]

Mitochondrial DNA Fragment Dynamics in Acute and Chronic Human Immunodeficiency Virus: Insights From Human and Nonhuman Primate Models

Sun J, Nidadavolu LS, Hsu HY, Rajagopal RG, Astemborski J, Wu Y, Jiang Y, Sacha JB, Kievit P, Jamieson BD, Roberts CT, Kirk GD, Brown[...]

CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis

Park D, Varda M, Yeremian S, Hwang A, Huang C. CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis. Target[...]